Parent Artery Reconstruction for Large or Giant Cerebral Aneurysms Using the Tubridge Flow Diverter: A Multicenter, Randomized, Controlled Clinical Trial (PARAT)

Liu, J.-m.; Zhou, Yu; Li, Yi; Li, T.; Leng, Bing; Zhang, P.; Liang, Guobiao; Huang, Qinghai; Yang, Pengfei; Shi, Huaizhang; Zhang, J.; Wan, Jieqing; He, Wei; Liang, Chunguang; Zhu, Gang; Xu, Yi; Hong, Bo; Yang, Xinjian; Bai, Weixing; Tian, Ye; Zhang, H.; Li, Zhi; Li, Q.; Zhao, Rui; Fang, Yibin; Zhao, Kaijun

doi:10.3174/ajnr.a5619

Cited by 78 publications

(75 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But the result need to be taken seriously, not all patients can compensate adequately after unilateral internal carotid artery occlusion, ischemic events may occur once compensation is insu cient. One meta-analyses indicated ischemic rates after ow diverter implantation was 7.5% [26] and a 9%-10% incidence of ischemic events should be anticipated when using ow diverters for large aneurysms [12]. We did not encounter hemorrhagic complications, and the morbidity and mortality rates were both 0%.…”

Section: Discussionmentioning

confidence: 81%

“…Up to now, there has been no single report on the therapeutic effect of TFD for LCCAs, in a clinical trial of liu et al [12], 37 patients with paraclinoid or cavernous aneurysms (aneurysm size 21.8 7.5, 10.0-45mm) were included, with a 6-month complete embolization rate of 75.7%. The article reported one-year mortality rate of 4.88%, hemorrhagic stroke and ischemic stroke related to target vessel was 6.1% and 9.76% respectively (These calculations include aneurysms of all sites, and was not a simple cavernous segment aneurysm).…”

Section: Discussionmentioning

confidence: 99%

“…Previously, a multicenter, prospective, randomized, controlled clinical trial veri ed the safety and e cacy of the TFD in unruptured large and giant intracranial aneurysms [12]. However, as a novel device, outcomes of TFDs to treat large CCAs (LCCAs, 10-25mm) have not yet been clari ed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluating the TubridgeTM flow diverter for large cavernous carotid artery aneurysms

Jia

Wang

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The TubridgeTM flow diverter (TFD) was recently developed in China; however, its safety and efficacy in treating large cavernous carotid artery aneurysms (LCCAs) are unclear.Our objective was to evaluate the safety and efficacy of the TFD in patients receiving TFDs to treat LCCAs (10–25 mm). Methods: Between June 2013 and May 2014, seven patients with LCCAs were enrolled in our study, and all seven patients underwent TFD implantation combined with coils.Results: Angiographic follow-up images were available for all seven patients at a median of 57.5 ± 16.7 (range, 6–69) months. Seven patients obtained favorable angiographic results defined as O’Kelly–Marotta Scale C and D. Clinical follow-up data were available for all seven patients at a median of 73.32 ± 3.6 (range, 66–78) months. No patients developed new neurological deficits. Six patients achieved a modified Rankin scale score of 0, and diplopia improved in the remaining patient.Conclusions: Results were excellent for the aneurysms treated with TFDs in our patients with LCCAs. TFDs are feasible for the treatment of LCCAs, but a multicenter, controlled clinical trial is needed to evaluate the long term safety and efficacy of the TFD to treat LCCAs.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the TubridgeTM flow diverter for large cavernous carotid artery aneurysms

Jia

Wang

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…But the result need to be taken seriously, not all patients can compensate adequately after unilateral internal carotid artery occlusion, ischemic events may occur once compensation is insu cient. One meta-analyses indicated ischemic rates after ow diverter implantation was 7.5% 25 and a 9%-10% incidence of ischemic events should be anticipated when using ow diverters for large aneurysms 12 . We did not encounter hemorrhagic complications, and the morbidity and mortality rates were both 0%.…”

Section: Discussionmentioning

confidence: 99%

“…Previously, a multicenter, prospective, randomized, controlled clinical trial veri ed the safety and e cacy of the TFD in unruptured large and giant intracranial aneurysms 12 . However, as a novel device, outcomes of TFDs to treat large CCAs (LCCAs, 10-25 mm) have not yet been clari ed.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the TubridgeTM Flow Diverter for Large Cavernous Carotid Artery Aneurysms

Jia¹,

Wang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The TubridgeTM flow diverter (TFD) was recently developed in China; however, its safety and efficacy in treating large cavernous carotid artery aneurysms (LCCAs) are unclear.Objective: To evaluate the safety and efficacy of the TFD in patients receiving TFDs to treat LCCAs (10–25 mm). Methods: Between June 2013 and May 2014, seven patients with LCCAs were enrolled in our study, and all seven patients underwent TFD implantation combined with coils.Results: Angiographic follow-up images were available for all seven patients at a median of 57.5 ± 16.7 (range, 6–69) months. Seven patients obtained favorable angiographic results defined as O’Kelly–Marotta Scale C and D. Clinical follow-up data were available for all seven patients at a median of 73.32 ± 3.6 (range, 66–78) months. No patients developed new neurological deficits. Six patients achieved a modified Rankin scale score of 0, and diplopia improved in the remaining patient.Conclusions: Results were excellent for the aneurysms treated with TFDs in our patients with LCCAs. TFDs are feasible for the treatment of LCCAs, but a multicenter, controlled clinical trial is needed to evaluate the long term safety and efficacy of the TFD to treat LCCAs.

show abstract

Toward the Development of a Shape Memory Polymer for Individualized Endovascular Therapy of Intracranial Aneurysms Using a 3D‐Printing/Leaching Method

Pineda-Castillo,

Cabaniss,

Aboukeila

et al. 2023

Adv Eng Mater

View full text Add to dashboard Cite

Endovascular treatment of intracranial aneurysms (ICA) aims to occlude the aneurysm space for preventing ICA growth/rupture. Modern endovascular techniques are still limited by lower complete occlusion rates, frequently leading to aneurysm growth, rupture and re‐operation. In this work, we propose shape memory polymer (SMP)‐based embolic devices that could advance the effectiveness of ICA therapy by facilitated individualized ICA occlusion. Specifically, we develop an 3D‐printing/leaching method for the fabrication of 3D‐SMP devices that can be tailored to patient‐specific aneurysm geometries that are obtained from computed tomography angiography. We demonstrate that this method allows the fabrication of highly porous, compressible foams with unique shape memory properties and customizable microstructure. In addition, the SMP foams exhibit great shape recovery, anisotropic mechanical properties, and the capability to occlude in‐vitro models with individualized geometries. Collectively, this study indicates that the proposed method will have the potential to advance the translation of coil‐ and stent‐free embolic devices for individualized treatment of saccular ICAs, targeting complete and long‐term durable aneurysm occlusion.This article is protected by copyright. All rights reserved.

show abstract

Parent Artery Reconstruction for Large or Giant Cerebral Aneurysms Using the Tubridge Flow Diverter: A Multicenter, Randomized, Controlled Clinical Trial (PARAT)

Cited by 78 publications

References 35 publications

Evaluating the TubridgeTM flow diverter for large cavernous carotid artery aneurysms

Evaluating the TubridgeTM flow diverter for large cavernous carotid artery aneurysms

Evaluating the TubridgeTM Flow Diverter for Large Cavernous Carotid Artery Aneurysms

Toward the Development of a Shape Memory Polymer for Individualized Endovascular Therapy of Intracranial Aneurysms Using a 3D‐Printing/Leaching Method

Contact Info

Product

Resources

About